AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT07218809. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
Study identification
- NCT ID
- NCT07218809
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 1,100 participants
Conditions and interventions
Conditions
Interventions
- AZD5335 Drug
- Mirvetuximab Soravtansine (MIRV) Drug
- Paclitaxel Drug
- Pegylated liposomal Doxorubicin (PLD) Drug
- Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2025
- Primary completion
- Nov 16, 2028
- Completion
- May 26, 2030
- Last update posted
- Jan 15, 2026
2025 – 2030
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fort Lauderdale | Florida | 33316 | Not yet recruiting |
| Research Site | Jupiter | Florida | 33458 | Recruiting |
| Research Site | Evanston | Illinois | 60201 | Not yet recruiting |
| Research Site | Peoria | Illinois | 61637 | Not yet recruiting |
| Research Site | Urbana | Illinois | 61801 | Not yet recruiting |
| Research Site | Towson | Maryland | 21204 | Not yet recruiting |
| Research Site | Burlington | Massachusetts | 01805 | Not yet recruiting |
| Research Site | Worcester | Massachusetts | 01655 | Not yet recruiting |
| Research Site | Minneapolis | Minnesota | 55404 | Not yet recruiting |
| Research Site | Omaha | Nebraska | 68114 | Not yet recruiting |
| Research Site | Las Vegas | Nevada | 89106 | Not yet recruiting |
| Research Site | The Bronx | New York | 10461 | Not yet recruiting |
| Research Site | Dayton | Ohio | 45459 | Recruiting |
| Research Site | Sylvania | Ohio | 43560 | Not yet recruiting |
| Research Site | San Antonio | Texas | 78229 | Not yet recruiting |
| Research Site | Tyler | Texas | 75702 | Not yet recruiting |
| Research Site | Fairfax | Virginia | 22031 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07218809, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2026 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07218809 live on ClinicalTrials.gov.